StockData
BioVie Inc. logo

BioVie Inc. (BIVI) shareholders

BIVINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as BIVIW
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$1.00−0.08 (-7.84%)

Close on Nov 17, 2026Market cap $7.51MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
1M
Shares held, 13F filers
Institutional holders
36
6 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
5 buys · 0 sales
Net bought $52.02K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Terren S. Peizer
Joint filing with Acuitas Group Holdings, LLC (15.80%)
3,050,39415.80%13D (active) amendmentJun 25, 2025
Morgan Stanley Smith Barney LLC
Joint filing with Morgan Stanley (11.90%)
896,82211.90%13G (passive) amendmentJul 31, 2026
Alta Partners LLC687,3218.40%13G (passive)Aug 12, 2026
Do Cuong V
Joint filing with Do & Rickles Investments, LLC (5.02%)
399,0185.03%13D (active)Jan 5, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of BIVIValueChange% of portfolio
Morgan Stanley605,471–$1.17M+530,2500.00%
Diametric Capital, LP256,636–$497.87K−113,3640.05%
Renaissance Technologies LLC127,918–$248.16K+60,0000.00%
Citadel Advisors LLC95,952–$186.15K+50,6600.00%
Vanguard Capital Management LLC70,906–$137.56K−13,1610.00%
Geode Capital Management, LLC70,752–$137.26K−13,4510.00%
Philadelphia Trust Co50,010–$97.00K−25,0000.01%
Vanguard Fiduciary Trust Co37,557–$72.86K–0.00%
Jane Street Group, LLC35,860–$69.57K+13,0690.00%
Prelude Capital Management, LLC32,583–$63.21K−59,4800.00%
Cambridge Investment Research Advisors, Inc.27,632–$54.00KNew0.00%
Northern Trust Corp21,820–$42.33K+7,6310.00%
Persistent Asset Partners Ltd14,996–$29.09KNew0.01%
XTX Topco Ltd14,228–$27.60K−6,9980.00%
Caprock Group, LLC11,300–$21.92KNew0.00%
Allworth Financial LP5,600–$10.86K–0.00%
UBS Group AG2,175–$4.22K+2,1690.00%
Tower Research Capital LLC (TRC)2,064–$4.00K−5,4760.00%
PNC Financial Services Group, Inc.1,000–$1.94K–0.00%
SBI Securities Co., Ltd.867–$1.68K+6360.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares heldNew / addedReduced / closedShares boughtShares sold
Q2 2026361M6 / 811 / 31M0M
Q1 2026331M7 / 75 / 70M0M
Q4 2025351M7 / 510 / 40M0M
Q3 2025321M31 / 10 / 01M0M
Q2 202510M1 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

6 funds held BIVI in Q2 2026, 51% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of BIVIValue% of fundAs of
Vanguard Extended Market Index Fund70,906–$137.56K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund55,453–$78.74K0.00%May 31, 2026
Fidelity Series Total Market Index Fund10,898–$15.48K0.00%May 31, 2026
Fidelity Total Market Index Fund2,401–$3.41K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund230–$3270.00%May 31, 2026
Blackstone Alternative Multi-Strategy Fund10–$190.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Cuong V. DoPresident & CEO, Director28,609Nov 16, 2026
Joseph M. PalumboChief Medical Officer6,036Aug 28, 2026
Joanne Wendy KimChief Financial Officer3,441Aug 28, 2026
Amy Suzon ChappellDirector727Aug 28, 2026
Sigmund RogichDirector36,926Jan 9, 2026
Kameel D. FaragDirector–Jan 9, 2026
James Paul LangDirector68,622Jan 9, 2026
Michael Edward ShermanDirector20,679Jan 9, 2026
Robert J. HaririDirector42,254Jan 7, 2025
Richard J. BermanDirector40,643Jan 7, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Cuong V. Do
President & CEO, Director
Nov 13, 2026Buy+2,500$1.16$2.91K18,617
Amy Suzon Chappell
Director
Aug 28, 2026Buy+727$2.16$1.57K727
Joseph M. Palumbo
Chief Medical Officer
Aug 28, 2026Buy+4,843$2.16$10.46K6,036
Joanne Wendy Kim
Chief Financial Officer
Aug 28, 2026Buy+2,500$2.18$5.45K3,441
Cuong V. Do
President & CEO, Director
Aug 27, 2026Buy+15,210$2.08$31.64K16,117
Cuong V. Do
President & CEO, Director
Aug 7, 2025Buy+5,000––9,992
Sigmund Rogich
Director
Nov 20, 2024Award+32,700––36,926
Richard J. Berman
Director
Nov 20, 2024Award+34,200––40,643
Joanne Wendy Kim
Chief Financial Officer
Jun 24, 2024Award+73,000––112,196
Joanne Wendy Kim
Chief Financial Officer
Jun 24, 2024Tax withholding−18,250$0.47$8.58K93,940
Cuong V. Do
President & CEO, Director
Jun 24, 2024Tax withholding−42,000$0.47$19.74K551,948
Cuong V. Do
President & CEO, Director
Jun 24, 2024Award+168,000––593,948
Joseph M. Palumbo
Chief Medical Officer
Jun 24, 2024Award+116,000––148,196
Joseph M. Palumbo
Chief Medical Officer
Jun 24, 2024Tax withholding−29,000$0.47$13.63K119,196
Cuong V. Do
President & CEO, Director
Mar 4, 2024Buy+10,000––435,854
Joanne Wendy Kim
Chief Financial Officer
Feb 15, 2024Tax withholding−2,476$1.18$2.92K39,196
Cuong V. Do
President & CEO, Director
Feb 15, 2024Tax withholding−4,953$1.18$5.84K425,948
Joseph M. Palumbo
Chief Medical Officer
Feb 15, 2024Tax withholding−2,476$1.18$2.92K32,196
Joanne Wendy Kim
Chief Financial Officer
Dec 11, 2023Award+5,000––44,148
Steve Gorlin
Director
Dec 1, 2023Sale−75,680$1.69$127.90K46,358
Cuong V. Do
President & CEO, Director
Nov 30, 2023Buy+10,000$1.78$17.80K68,759
Steve Gorlin
Director
Nov 9, 2023Award+46,358––122,038
Richard J. Berman
Director
Nov 9, 2023Award+51,830––69,235
Robert J. Hariri
Director
Nov 9, 2023Award+42,254––42,254
Sigmund Rogich
Director
Nov 9, 2023Award+42,254––42,254
Steve Gorlin
Director
Sep 5, 2023Sale−8,560$3.05$26.11K75,680
Richard J. Berman
Director
Aug 22, 2023Sale−10,805$3.50$37.82K16,789
Cuong V. Do
CEO & President, Director
Jun 29, 2023Award+149,500––425,854
Cuong V. Do
CEO & President, Director
Jun 21, 2023Option exercise+41,506––271,401
Richard J. Berman
Director
Jun 7, 2023Sale−5,984$5.81$34.77K23,210
Richard J. Berman
Director
May 22, 2023Sale−5,000$6.50$32.50K29,194
Richard J. Berman
Director
Mar 28, 2023Sale−2,613$8.52$22.26K34,194
Richard J. Berman
Director
Mar 28, 2023Sale−5,000$8.52$42.60K36,807
Richard J. Berman
Director
Mar 27, 2023Sale−3,371$8.52$28.72K41,807
Joanne Wendy Kim
Chief Financial Officer
Feb 16, 2023Tax withholding−2,476$5.51$13.64K41,672
Cuong V. Do
President & CEO, Director
Feb 16, 2023Tax withholding−4,953$5.51$27.29K430,901
Joseph M. Palumbo
Chief Medical Officer
Feb 16, 2023Tax withholding−2,476$5.51$13.64K34,672
Clarence N. Ahlem
EVP Neuroscience Product Dev.
Feb 16, 2023Tax withholding−2,476$6.12$15.15K37,148
Penelope Markham
EVP Liver Cirrhosis R&D
Feb 16, 2023Tax withholding−2,476$6.12$15.15K47,841
Joseph M. Palumbo
Chief Medical Officer
Feb 16, 2023Tax withholding−2,476$6.12$15.15K37,148
Cuong V. Do
CEO & President, Director
Feb 16, 2023Tax withholding−4,953$6.12$30.31K229,895
Christopher Reading
EVP Neuroscience R&D
Feb 16, 2023Tax withholding−2,476$6.12$15.15K37,148
Joanne Wendy Kim
Chief Financial Officer
Feb 16, 2023Tax withholding−2,476$6.12$15.15K39,148
Joseph M. Palumbo
Chief Medical Officer
Nov 23, 2022Award+39,624––39,624
Robert J. Hariri
Director
Nov 23, 2022Award+34,240––34,240
Penelope Markham
EVP Liver Cirrhosis R&D
Nov 23, 2022Award+39,624––50,317
James Paul Lang
Director
Nov 23, 2022Award+43,578––68,622
Clarence N. Ahlem
EVP Neuroscience Product Dev.
Nov 23, 2022Award+39,624––39,624
Steve Gorlin
Director
Nov 23, 2022Award+34,240––84,240
Richard J. Berman
Director
Nov 23, 2022Award+43,578––45,178
Christopher Reading
EVP Neuroscience R&D
Nov 23, 2022Award+39,624––39,624
Joanne Wendy Kim
Chief Financial Officer
Nov 23, 2022Award+39,624––41,624
Cuong V. Do
CEO & President, Director
Nov 23, 2022Award+79,248––234,848
Terren S. Peizer
Director, 10% owner
Aug 15, 2022Award+3,636,364$1.65$6.00M23,166,210
Jonathan M. Adams
EVP Liver Cirrhosis Programs
Feb 2, 2022Gift−1,000––48,630
Cuong V. Do
President & CEO, Director
Dec 31, 2021Award+21,710––58,759
Joanne Wendy Kim
CFO
Dec 7, 2021Buy+2,000$5.40$10.80K2,000
Jonathan M. Adams
EVP Liver Cirrhosis Programs
Jun 16, 2021Gift−10,000––49,630
Terren S. Peizer
Director, 10% owner
Jun 10, 2021Award+8,361,308––19,529,846
Steve Gorlin
Director
Nov 3, 2020Buy+2,430$7.95$19.32K45,100

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
1M shares short
Days to cover
3.7
At 0M shares a day
Change since last report
+8.2%
From 1M shares
Short volume, 20 days
54.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BioVie's stock actually held short. Settlement fails (shares not delivered on time) peaked at 808,725 shares on Aug 21, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Steve Gorlin
Director
Dec 1, 202325,680$43.40KDec 1, 2023Performance Stock Units
Deborah Gorlin
Wife of director Steve Gorlin
Dec 1, 202350,000$84.50KDec 1, 2023Open Market Purchase
Steve Gorlin
Director
Sep 5, 20238,560$26.11KSep 5, 2023Performance Stock Units

See a number that looks wrong?